Coronary Artery Disease (CAD)

Cardiovascular disease (CVD), including heart disease and stroke, is the leading cause of death worldwide, accounting for 17.7 million deaths annually, or approximately one-third of all deaths globally.

Learn more about CAD and the future of biomarker-based clinical research

THE NEED FOR PERSONALISED THERAPY IN CAD

 

Studies are beginning to unravel the potential of personalised medicine in patients with CAD, in that targeting inflammation in those with residual inflammatory risk appears to be a viable strategy for ensuring that the right patients receive the right therapy at the right time. Learn more here >>

  • Twitter - White Circle
  • LinkedIn - White Circle

The PlaqueTec LBS™ is currently approved for use in the European Economic Area (EEA) only. PlaqueTec is in the process of  filing with regulatory authorities in other markets.

PlaqueTec © 2018